Department of Head and Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy.
Unit of Oral Surgery and Implantology, Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy.
BMC Oral Health. 2024 Feb 5;24(1):183. doi: 10.1186/s12903-024-03938-y.
In the pediatric oncology population, oral mucositis as a consequence of chemotherapy is a highly prevalent complication which strongly affects both the quality of life and treatment possibilities of the patients. Still, the etiopathological mechanisms carrying to its development are not fully understood, although a possible role of oral dysbiosis has been previously investigated with unclear conclusions. The aim of this systematic review was to assess the available evidence on the role of microbiota in the development of oral mucositis.
A systematic literature search was performed following PRISMA guidelines. Three electronic databases were searched up until April 2023 and a following manual search included the reference lists of the included studies and reviews. Studies reporting microbiological and clinical data of pediatric patients treated by antineoplastic drugs were included.
Thirteen studies met the inclusion criteria, reporting an average mucositis prevalence of 57,6%. Candida albicans infections were frequently observed in studies performing microbiological analysis on oral lesions, in contrast with the low rate detection of the Herpes simplex viruses. Bacterial species such as coagulase-negative Staphylococci and Streptococcus viridans were detected more frequently on lesion sites. Studies reporting a quantitative analysis of the general flora did not show comparable results. Risk of bias assessment among studies was generally considered high or very high.
While the specific role of certain microbiological agents, such as Candida albicans, was frequently reported among studies, data regarding the general dynamics of oral microbiota in the development of oral mucositis are lacking in the current literature. Thus, more studies are needed to provide the knowledge required in order to improve protocols for the prevention and treatment of this threatening complication.
在儿科肿瘤患者中,化疗引起的口腔黏膜炎是一种高发并发症,严重影响患者的生活质量和治疗选择。尽管先前已经研究了口腔菌群失调在其发展中的可能作用,但导致其发生的确切病理生理机制仍未完全阐明。本系统综述的目的是评估现有关于微生物群在口腔黏膜炎发展中的作用的证据。
按照 PRISMA 指南进行系统文献检索。检索了三个电子数据库,截止到 2023 年 4 月,并进行了后续的手动搜索,包括纳入研究和综述的参考文献列表。纳入报告接受抗肿瘤药物治疗的儿科患者微生物学和临床数据的研究。
符合纳入标准的研究共有 13 项,报告口腔黏膜炎的平均患病率为 57.6%。在进行口腔病变微生物学分析的研究中,常观察到白色念珠菌感染,而单纯疱疹病毒的检出率较低。在病变部位更常检测到凝固酶阴性葡萄球菌和草绿色链球菌等细菌种类。报告一般菌群定量分析的研究未显示出可比的结果。研究的偏倚风险评估普遍被认为较高或很高。
虽然某些微生物病原体(如白色念珠菌)的特定作用在研究中经常被报道,但关于口腔黏膜炎发生时口腔微生物群的一般动态的相关数据在当前文献中缺乏。因此,需要更多的研究来提供所需的知识,以改善这种威胁性并发症的预防和治疗方案。